Research programme: ERN1 protein inhibitors - MannKind Corporation

Drug Profile

Research programme: ERN1 protein inhibitors - MannKind Corporation

Alternative Names: Inositol requiring enzyme-1 inhibitor; IRE-1α inhibitor; MKC 204; Mkc 8866; MKC-3946

Latest Information Update: 29 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MannKind Corporation
  • Class Small molecules
  • Mechanism of Action ERN1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia
  • No development reported Multiple myeloma

Most Recent Events

  • 22 Jun 2017 Preclinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
  • 22 Jun 2017 Pharmacodynamics data from preclinical trials in Acute lymphoblastic leukaemia were presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-myeloma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top